Second time not the charm

Gensia Pharmaceutical Inc.'s presentation at the American College of Cardiology meeting of Phase III data on Arasine in coronary artery bypass surgery failed to reassure investors, who pushed the stock down 30 percent last week to $16..

The stock had been languishing in the 20s since unhappy investors sold off shares after the first look at the data in September.